Altimmune (NASDAQ:ALT) Now Covered by Analysts at William Blair

Analysts at William Blair started coverage on shares of Altimmune (NASDAQ:ALT) in a research note issued on Friday,Briefing.com Automated Import reports. The brokerage set a “market perform” rating on the stock.

ALT has been the subject of several other research reports. UBS Group started coverage on shares of Altimmune in a research report on Tuesday, November 12th. They issued a “buy” rating and a $26.00 price target for the company. HC Wainwright reissued a “buy” rating and set a $12.00 target price on shares of Altimmune in a research note on Wednesday, February 5th. Finally, Stifel Nicolaus assumed coverage on Altimmune in a research report on Wednesday, January 8th. They issued a “buy” rating and a $18.00 price target on the stock. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Altimmune has an average rating of “Moderate Buy” and an average price target of $20.83.

Altimmune Trading Up 8.1 %

ALT stock opened at $6.42 on Friday. The business’s fifty day moving average price is $6.88 and its 200 day moving average price is $7.18. Altimmune has a 12-month low of $5.28 and a 12-month high of $14.84. The company has a market capitalization of $456.59 million, a PE ratio of -4.14 and a beta of 0.19.

Altimmune (NASDAQ:ALT) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.01. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. The business had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.00 million. Research analysts predict that Altimmune will post -1.35 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ALT. Larson Financial Group LLC acquired a new position in Altimmune in the third quarter valued at approximately $31,000. SBI Securities Co. Ltd. acquired a new position in shares of Altimmune in the 4th quarter valued at $45,000. Virtus ETF Advisers LLC purchased a new position in shares of Altimmune in the 4th quarter valued at $60,000. Cullen Frost Bankers Inc. acquired a new stake in Altimmune during the 4th quarter worth $72,000. Finally, 180 Wealth Advisors LLC purchased a new stake in Altimmune in the fourth quarter valued at $78,000. Hedge funds and other institutional investors own 78.05% of the company’s stock.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.